FindTrial
Sign In

VRC-HIVADV014-00-VP

BIOLOGICAL15 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Adaptive ImmunityHIVHIV InfectionsHIV NegativeHealthyInnate Immunity

Phase 1

Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers
CompletedNCT00083330
National Institute of Allergy and Infectious Diseases (NIAID)Healthy, HIV Infections
Start: 2004-05-18End: 2009-10-01Target: 36Updated: 2017-07-02
Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052
CompletedNCT00091416
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 2006-05-31Updated: 2021-10-14
HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers
CompletedNCT00102089
National Institute of Allergy and Infectious Diseases (NIAID)Healthy, HIV Infections
Start: 2005-01-18End: 2007-10-10Target: 32Updated: 2017-07-02
Vaccine Treatment for HIV-Infection
CompletedNCT00108654
National Institute of Allergy and Infectious Diseases (NIAID)Healthy
Start: 2005-04-13End: 2008-01-15Target: 14Updated: 2017-07-02
Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults
CompletedNCT00119873
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 2006-10-31Updated: 2021-10-14
Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults
CompletedNCT00123968
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2006-05-31End: 2012-06-30Updated: 2021-11-09
Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
CompletedNCT00124007
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2005-11-30End: 2007-04-30Updated: 2021-11-01
Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults
CompletedNCT00270218
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2006-02-28End: 2007-08-31Updated: 2021-10-14
Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients
CompletedNCT00270465
National Institute of Allergy and Infectious Diseases (NIAID)HIV
Start: 2005-12-21End: 2009-06-25Target: 17Updated: 2017-07-02
Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults
CompletedNCT00384787
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2006-11-30End: 2012-12-31Updated: 2021-10-14
Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection
CompletedNCT00709605
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2008-06-25End: 2014-05-20Updated: 2019-12-17
Immune Responses to Two Experimental HIV Vaccines in Healthy Adults
CompletedNCT01386489
National Institute of Allergy and Infectious Diseases (NIAID)Adaptive Immunity, HIV Negative, Innate Immunity
Start: 2011-06-17End: 2014-03-19Updated: 2019-12-16

Phase 2

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants
CompletedNCT00125970
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2005-09-30End: 2010-01-31Updated: 2021-10-15
Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults
WithdrawnNCT00415649
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Updated: 2021-11-01
Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa
WithdrawnNCT00498056
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Updated: 2021-11-01

Related Papers

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
PLoS Pathogens2021-11-292 citations
Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
PLoS ONE2014-09-295 citations
Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.
2013-03-1244 citations
Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
2011-09-1235 citations
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
2011-08-03117 citations
Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya.
2011-01-2114 citations
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).
2010-10-2745 citations
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
2010-09-2176 citations
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
2010-02-02113 citations
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
2010-02-0182 citations
Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa.
2009-04-1021 citations